Please Wait.....
Report
South Korea Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 100 Pages I Mordor Intelligence
South Korea Drug Delivery Devices Market Analysis
The South Korea drug delivery devices market stands at USD 5.08 billion in 2025 and is forecast to reach USD 7.63 billion by 2030, advancing at an 8.47% CAGR. Rising life expectancy, rapid urbanization, and strong domestic production underpin this growth. A national policy focus on chronic disease management, coupled with high digital?health adoption, is accelerating uptake of connected pumps, smart inhalers, and other patient-centric technologies. Government fast-track approvals for breakthrough devices shorten launch timelines, while a broad biologic pipeline pushes demand for advanced injectable platforms. Competitive intensity is increasing as domestic innovators align with global leaders to commercialize novel formats across oncology, diabetes, and pain care.
South Korea Drug Delivery Devices Market Trends and Insights
Ageing Population Coupled with High Chronic Disease Burden
More than 20% of citizens will be 65 or older by end-2025, and 54.8% of these older adults manage multiple chronic conditions.Complex medication schedules heighten demand for user-friendly devices that deliver several drugs with minimal disruption. Frequent comorbid clusters, such as cardiometabolic and arthritis, are steering suppliers toward combination systems tailored to specific patient groups. Out-of-pocket costs nearly triple for multimorbid individuals, motivating insurers to endorse efficient delivery tools that improve adherence and lower total care expenditure.
Technological Advancement and Supportive Government Policies
National programs like the High-Tech Bio Initiative and the 1st Master Plan for Fostering and Supporting the Medical Device Industry provide funding, testbeds, and accelerated reviews that shorten commercialization cycles. Reforms at the Ministry of Food and Drug Safety (MFDS) carve dedicated pathways for breakthrough devices, shrinking approval windows and encouraging early market entry.[3] Nanotechnology-enabled carriers, now progressing through clinical pipelines, demonstrate improved drug loading and targeted release, reinforcing South Korea's ambition to lead AI-integrated, patient-centric healthcare.
Stringent Approval and Vigilance Delaying Novel Device Launches
MFDS classifies devices by risk, and Classes II-IV undergo extensive dossier reviews, including quality, safety, and sometimes clinical data. For foreign firms, the mandatory Korean License Holder adds administrative layers. Post-market surveillance lists track 52 device categories, imposing ongoing reporting that can deter small entrants.
Other drivers and restraints analyzed in the detailed report include:
High Digital Health Adoption Supporting Smart Pumps & Connected Inhalers / Expanding Domestic Biosimilar & Biologic Pipeline Requiring Injectable Formats / Risks and Safety Concerns Related to Devices /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Injectable platforms account for 36.78% of South Korea drug delivery devices market share in 2024, reflecting their versatility across diabetes, oncology, and autoimmune therapy. Demand remains steady as biologics dominate development pipelines. Implantable systems, posting a 10.46% CAGR to 2030, benefit from biocompatible polymers that release drugs over months, lowering dosing frequency for chronic pain and hormone disorders. Clinical data from domestic cohorts confirm reduced opioid exposure when intrathecal pumps replace systemic analgesics.
Wearable injectors, fixed?dose autoinjectors, and on-body pumps enhance self-management. Transdermal patches broaden options for neurological and pain conditions, with twice-weekly rivastigmine patches easing caregiver workloads. Inhalers, now integrating dose-tracking chips, link to mobile apps for personalized coaching. Nasal and ocular inserts remain niche but attract R&D interest for CNS drugs and ophthalmic biologics. Growing acceptance of these alternatives signals ongoing diversification within the South Korea drug delivery devices market.
Injectables cover 56.53% of administration routes in 2024, favored for their proven bioavailability and compatibility with complex molecules. Oral mucosal formats show the fastest 10.68% CAGR, drawing traction for rapid onset and ease of use. Thin films dissolving in seconds avoid first-pass metabolism, helping dysphagic patients adhere to regimens. The South Korea drug delivery devices market size for mucosal routes is projected to expand steadily alongside R&D investments that improve permeability enhancers and taste-masking agents.
Transdermal technology advances through micro?needle arrays that painlessly breach the stratum corneum and deliver steady plasma levels over several days. Respiratory applications hold a stable share as chronic obstructive pulmonary disease and asthma prevalence rises. Ocular and nasal routes gain strategic importance for vaccines and neuro-active peptides that target the brain, bypassing systemic clearance barriers.
The South Korea Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Transdermal, Ocular, and More), Application (Diabetes, Oncology, Cardiovascular Disorders and More), and End Users (Hospitals, Ambulatory Surgical Centres, and More). The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Baxter / Bayer / Roche / EOFlow Co., Ltd / Johnson&Johnson / Novartis / TDS Pharm / QuadMedicine Co., Ltd. / Daewon Pharmaceutical Co., Ltd. / Dongkook Pharmaceutical Co., Ltd. / Yuhan Corporation / Sanofi / Beckton Dickinson / Ypsomed / Medtronic / Terumo / Teva Pharmaceutical Industries / LG Chem / Icure Pharmaceutical Inc /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Ageing Population Coupled with High Burden Chronic Disease Burden
4.2.2 Technological Advancement and Supportive Government Policies
4.2.3 High Digital Health Adoption Supporting Smart Pumps & Connected Inhalers
4.2.4 Expanding Domestic Biosimilar & Biologic Pipeline Requiring Injectable Formats
4.2.5 Expansion of Home Healthcare
4.2.6 Intitivates for Manufacturing and Infrastructure Boost for Drug Delivery Devices
4.3 Market Restraints
4.3.1 Stringent Approval & Vigilance Delaying Novel Device Launches
4.3.2 Risks and Safety Concerns Related to Devices
4.3.3 HIRA Price Caps Compressing Premium Device Margins
4.3.4 Hospital Tender Bias Toward Domestic Vendors Limiting Foreign Manufacturers
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Device Type
5.1.1 Injectable Delivery Devices
5.1.2 Inhalation Delivery Devices
5.1.3 Infusion Pumps
5.1.4 Transdermal Patches
5.1.5 Implantable Drug Delivery Systems
5.1.6 Ocular Inserts & Delivery Implants
5.1.7 Nasal & Buccal Delivery Devices
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Inhalation
5.2.3 Transdermal
5.2.4 Oral Mucosal (Buccal & Sublingual)
5.2.5 Ocular
5.2.6 Nasal
5.3 By Application
5.3.1 Diabetes
5.3.2 Oncology
5.3.3 Cardiovascular Disorders
5.3.4 Respiratory Diseases
5.3.5 Infectious Diseases
5.3.6 Auto-immune & Others
5.4 By End User
5.4.1 Hospitals
5.4.2 Ambulatory Surgical Centers
5.4.3 Home Healthcare Settings
5.4.4 Specialty Clinics
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Baxter International Inc.
6.4.2 Bayer AG
6.4.3 F. Hoffmann-La Roche AG
6.4.4 EOFlow Co., Ltd
6.4.5 Johnson & Johnson
6.4.6 Novartis AG
6.4.7 TDS Pharm
6.4.8 QuadMedicine Co., Ltd.
6.4.9 Daewon Pharmaceutical Co., Ltd.
6.4.10 Dongkook Pharmaceutical Co., Ltd.
6.4.11 Yuhan Corporation
6.4.12 Sanofi
6.4.13 BD (Becton, Dickinson and Company)
6.4.14 Ypsomed AG
6.4.15 Medtronic plc
6.4.16 Terumo Corporation
6.4.17 Teva Pharmaceuticals
6.4.18 LG Chem
6.4.19 Icure Pharmaceutical Inc
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security